Since altered BDNF/TrkB signaling has been involved in AD pathology, various therapeutic approaches, such as exogenous mature BDNF delivery, BDNF gene therapy, and cell therapy, have been investigated [158,159]. The gene discussed is NTRK2; the disease is Alzheimer disease.